Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: a Norwegian 2-year prospective multicenter pilot study.
Adolescent
Anti-Inflammatory Agents
/ therapeutic use
Arthritis, Juvenile
/ diagnostic imaging
Child
Female
Glucocorticoids
/ therapeutic use
Humans
Injections, Intra-Articular
Magnetic Resonance Imaging
Male
Methylprednisolone Acetate
/ therapeutic use
Norway
Pilot Projects
Prospective Studies
Temporomandibular Joint Disorders
/ diagnostic imaging
Treatment Outcome
Triamcinolone Acetonide
/ analogs & derivatives
Adverse events
Efficacy
Intraarticular corticosteroids
Juvenile idiopathic arthritis
Magnetic resonance imaging
Temporomandibular arthritis
Temporomandibular joint
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
07
04
2020
accepted:
03
09
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
3
8
2021
Statut:
epublish
Résumé
Intraarticular corticosteroids (IACs) have been used to treat temporomandibular joint (TMJ) arthritis. However, prospective clinical studies with magnetic resonance imaging (MRI) scoring are lacking. The aim of this study was to examine efficacy and safety of a single IAC in the TMJ in adolescents with juvenile idiopathic arthritis (JIA) in a clinical setting. In this Norwegian prospective multicenter pilot study 15 patients with JIA (mostly persistent oligoarthritis or RF negative polyarthritis categories) and a clinically and MRI-verified diagnosis of TMJ arthritis were treated with IACs and followed for 2 years. Demographics, systemic medication, general disease activity and outcome measures were recorded including a pain-index score and maximal incisal opening (MIO). Inflammation and bone damage scores were assessed, using two recently published MRI scoring systems with masked radiological evaluation. Among the 15 patients, 13 received a single IAC (5 bilateral), and 2 repeated IACs once unilaterally. Thus, the total number of IACs was 22. Median age was 15 years and the majority had an age not thought of as critical regarding mandibular growth retardation due to steroid injection. During the 2-year observation period systemic medication with disease modifying antirheumatic drugs (DMARDs) including biologics was initiated or adjusted in 10/15 (67%) patients. At the 2-months study visit after injection we observed a minimal improvement in MIO from median 44 (1st, 3rd quartiles; 36, 48) mm to 45 (43, 47) mm, p = 0.045 and decreased MRI mean additive inflammatory score from 4.4 ± 1.8 standard deviations (SD) to 3.4 ± 2.0, p = 0.040. From baseline to the 2-months follow-up pain improved in 6/11 patients but pain scores were not significantly improved. MRI-assessed damage increased in two patients with repeated IACs, and decreased in 3 patients but most of the patients were stable over the 2-year follow-up. Intra-rater repeatability of the MRI scoring system domains varied from poor to excellent. In this pilot study of predominately single IACs to the TMJ in combination with systemic treatment we observed improvement in MRI-assessed inflammation, mostly stable condylar bone conditions and minimal clinical improvement in adolescents with JIA and TMJ arthritis. No severe side effects were seen.
Sections du résumé
BACKGROUND
BACKGROUND
Intraarticular corticosteroids (IACs) have been used to treat temporomandibular joint (TMJ) arthritis. However, prospective clinical studies with magnetic resonance imaging (MRI) scoring are lacking. The aim of this study was to examine efficacy and safety of a single IAC in the TMJ in adolescents with juvenile idiopathic arthritis (JIA) in a clinical setting.
METHODS
METHODS
In this Norwegian prospective multicenter pilot study 15 patients with JIA (mostly persistent oligoarthritis or RF negative polyarthritis categories) and a clinically and MRI-verified diagnosis of TMJ arthritis were treated with IACs and followed for 2 years. Demographics, systemic medication, general disease activity and outcome measures were recorded including a pain-index score and maximal incisal opening (MIO). Inflammation and bone damage scores were assessed, using two recently published MRI scoring systems with masked radiological evaluation.
RESULTS
RESULTS
Among the 15 patients, 13 received a single IAC (5 bilateral), and 2 repeated IACs once unilaterally. Thus, the total number of IACs was 22. Median age was 15 years and the majority had an age not thought of as critical regarding mandibular growth retardation due to steroid injection. During the 2-year observation period systemic medication with disease modifying antirheumatic drugs (DMARDs) including biologics was initiated or adjusted in 10/15 (67%) patients. At the 2-months study visit after injection we observed a minimal improvement in MIO from median 44 (1st, 3rd quartiles; 36, 48) mm to 45 (43, 47) mm, p = 0.045 and decreased MRI mean additive inflammatory score from 4.4 ± 1.8 standard deviations (SD) to 3.4 ± 2.0, p = 0.040. From baseline to the 2-months follow-up pain improved in 6/11 patients but pain scores were not significantly improved. MRI-assessed damage increased in two patients with repeated IACs, and decreased in 3 patients but most of the patients were stable over the 2-year follow-up. Intra-rater repeatability of the MRI scoring system domains varied from poor to excellent.
CONCLUSIONS
CONCLUSIONS
In this pilot study of predominately single IACs to the TMJ in combination with systemic treatment we observed improvement in MRI-assessed inflammation, mostly stable condylar bone conditions and minimal clinical improvement in adolescents with JIA and TMJ arthritis. No severe side effects were seen.
Identifiants
pubmed: 32998740
doi: 10.1186/s12969-020-00464-3
pii: 10.1186/s12969-020-00464-3
pmc: PMC7528594
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Glucocorticoids
0
Methylprednisolone Acetate
43502P7F0P
Triamcinolone Acetonide
F446C597KA
triamcinolone hexacetonide
I7GT1U99Y9
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Références
Pediatr Rheumatol Online J. 2013 Apr 22;11:17
pubmed: 23607797
Pediatr Radiol. 2018 Mar;48(3):411-426
pubmed: 29134239
J Rheumatol. 2012 Dec;39(12):2352-8
pubmed: 23027886
AJR Am J Roentgenol. 2007 Jan;188(1):182-6
pubmed: 17179362
Acta Odontol Scand. 1999 Feb;57(1):16-22
pubmed: 10207531
J Rheumatol. 1998 Jul;25(7):1406-12
pubmed: 9676776
J Oral Maxillofac Surg. 2012 Aug;70(8):1802-7
pubmed: 22265164
Rheumatology (Oxford). 2011 Sep;50(9):1627-34
pubmed: 21561981
Arthritis Rheum. 2012 Jul;64(7):2366-74
pubmed: 22231288
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36
pubmed: 21717596
J Rheumatol. 2020 May 1;47(5):730-738
pubmed: 31523047
Rheumatology (Oxford). 2009 Jun;48(6):680-5
pubmed: 19386819
Eur J Oral Sci. 1995 Aug;103(4):214-8
pubmed: 7552951
Pediatr Rheumatol Online J. 2018 Apr 25;16(1):32
pubmed: 29695255
Semin Arthritis Rheum. 2016 Jun;45(6):717-32
pubmed: 26708936
Pain Res Manag. 2018 Sep 26;2018:7474608
pubmed: 30356427
Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82
pubmed: 21452260
J Rheumatol. 2001 Jul;28(7):1689-92
pubmed: 11469480
Rheumatology (Oxford). 2012 May;51(5):874-7
pubmed: 22210663
J Oral Maxillofac Surg. 2017 Apr;75(4):694-700
pubmed: 28718441
Pediatr Radiol. 2010 Sep;40(9):1498-504
pubmed: 20204611
J Oral Maxillofac Surg. 2018 Dec;76(12):2463-2465
pubmed: 30028954
Arthritis Care Res (Hoboken). 2018 May;70(5):758-767
pubmed: 28805021
Pediatr Radiol. 2016 Mar;46(3):331-41
pubmed: 26637998
J Rheumatol. 2011 Jul;38(7):1423-8
pubmed: 21498479
Arthritis Care Res (Hoboken). 2017 May;69(5):677-686
pubmed: 27564918
J Oral Maxillofac Surg. 2018 Jun;76(6):1200-1206
pubmed: 29391161
Orthod Craniofac Res. 2013 Aug;16(3):137-45
pubmed: 23324014
Arthritis Rheum. 2005 Nov;52(11):3563-9
pubmed: 16255045
J Rheumatol. 2011 May;38(5):938-53
pubmed: 21362761
J Rheumatol. 2008 Jun;35(6):1157-64
pubmed: 18398938
J Oral Rehabil. 2019 Jan;46(1):14-22
pubmed: 30252949
Br J Rheumatol. 1986 Feb;25(1):59-66
pubmed: 3080044
Arthritis Rheum. 2008 Apr;58(4):1189-96
pubmed: 18383394
J Oral Maxillofac Surg. 2016 Dec;74(12):2363-2369
pubmed: 27474460
J Pharm Bioallied Sci. 2015 Aug;7(Suppl 2):S687-90
pubmed: 26538944
J Rheumatol. 2015 Aug;42(8):1514-22
pubmed: 26034145
Int J Oral Maxillofac Surg. 2019 Aug;48(8):1032-1042
pubmed: 30704836
Semin Arthritis Rheum. 2013 Aug;43(1):63-70
pubmed: 23352251
J Orthod. 2010 Mar;37(1):6-15
pubmed: 20439922
J Rheumatol. 2020 Jun 1;47(6):909-916
pubmed: 31523042
AJR Am J Roentgenol. 2009 Oct;193(4):1148-54
pubmed: 19770341
J Oral Maxillofac Surg. 2016 Jul;74(7):1330-5
pubmed: 26896757
Eur J Orthod. 2008 Apr;30(2):111-9
pubmed: 18209214
J Rheumatol. 2011 Mar;38(3):510-5
pubmed: 21159837
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jul;108(1):114-23
pubmed: 19540449
World J Otorhinolaryngol Head Neck Surg. 2017 Jun 21;3(2):85-91
pubmed: 29204584
Pediatr Rheumatol Online J. 2015 Dec 21;13:62
pubmed: 26689191
Arthritis Rheum. 2009 May 15;61(5):658-66
pubmed: 19405003
J Rheumatol. 2019 May;46(5):518-522
pubmed: 30647179
Scand J Rheumatol. 2010;39(5):373-9
pubmed: 20615158
Int J Oral Maxillofac Surg. 2014 Aug;43(8):990-5
pubmed: 24794763
J Oral Facial Pain Headache. 2014 Winter;28(1):6-27
pubmed: 24482784